AR060795A1 - Moleculas quimericas fusionadas a matrilina 1, de uso terapeutico - Google Patents

Moleculas quimericas fusionadas a matrilina 1, de uso terapeutico

Info

Publication number
AR060795A1
AR060795A1 ARP070101321A ARP070101321A AR060795A1 AR 060795 A1 AR060795 A1 AR 060795A1 AR P070101321 A ARP070101321 A AR P070101321A AR P070101321 A ARP070101321 A AR P070101321A AR 060795 A1 AR060795 A1 AR 060795A1
Authority
AR
Argentina
Prior art keywords
fused
therapeutic use
matrilina
protein
chemical molecules
Prior art date
Application number
ARP070101321A
Other languages
English (en)
Inventor
Rivero Iraldo Bello
Roche Diamile Gonzalez
Cowley Jorge Victor Gavilondo
Meireles Rolando Paez
Nunez Anazuria Martinez
Santiago Glay Chinea
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR060795A1 publication Critical patent/AR060795A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Moléculas quiméricas fusionadas al péptido correspondiente al extremo carboxilo-de la Matrilina 1 humana mediante un espaciador flexible que les confiere un mayor tiempo de vida media en sangre y una actividad específica superior respecto a las moléculas no fusionadas. Reivindicacion 1: Proteína quimérica caracterizada porque contiene esencialmente el extremo carboxilo de la Matrilina 1, identificada en el listado de secuencias como Seq. ID. N°:19 desde el aminoácido numero 206 hasta el 246, y una proteína de uso terapéutico, fusionadas mediante un espaciador aminoacídico, la cual tiene una vida media y una actividad específica mayor que la proteína de uso terapéutico no fusionada.
ARP070101321A 2006-03-29 2007-03-29 Moleculas quimericas fusionadas a matrilina 1, de uso terapeutico AR060795A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060073 2006-03-29

Publications (1)

Publication Number Publication Date
AR060795A1 true AR060795A1 (es) 2008-07-16

Family

ID=38510311

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101321A AR060795A1 (es) 2006-03-29 2007-03-29 Moleculas quimericas fusionadas a matrilina 1, de uso terapeutico

Country Status (2)

Country Link
AR (1) AR060795A1 (es)
WO (1) WO2007110001A2 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021226A1 (en) * 1992-04-10 1993-10-28 The General Hospital Corporation Cartilage matrix protein and methods for use
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
CU23228A1 (es) * 2002-04-29 2007-09-26 Ct Ingenieria Genetica Biotech Fragmentos de anticuerpos especificos para el antigeno carcinoembrionario humano (cea) secuencias de sus regiones variables y vectores para la expresion microbiana de los mismos
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
FR2856070A1 (fr) * 2003-06-13 2004-12-17 Bionexis Molecules pour le ciblage et l'assemblage in situ de proteines therapeutiques et leur utilisation

Also Published As

Publication number Publication date
WO2007110001A2 (es) 2007-10-04
WO2007110001A3 (es) 2007-11-15

Similar Documents

Publication Publication Date Title
PE20090225A1 (es) Proteinas de fusion que degradan el peptido beta amiloide
UY31123A1 (es) Proteinas de fusion natriureticas
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
PE20090711A1 (es) Region constante de anticuerpo mutante
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
AR062030A1 (es) Proteinas de fusion de exendina
MD3292141T2 (ro) Proteine de fuziune
JP2014525901A5 (es)
AR062065A1 (es) Anticuerpo humanizado
NI201200134A (es) Polipéptidos agonistas que se enlazan a dr5
RU2016146198A (ru) Терапевтические dll4-связывающие белки
DK1761553T3 (da) MHC molecule-binding tumor-associated peptides
ES2571879T3 (es) Moléculas de una sola cadena de TNFSF
RU2014101697A (ru) Коагонисты рецепторов глюкагона/glp-1
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
NO20071592L (no) GLP-1 og exendinrelatert oppfinnelse
ATE474917T1 (de) Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
AR060862A1 (es) Proteinas de fusion rage, formulaciones y metodos de uso de estas
NO20082510L (no) En fremgangsmate for konsentrasjon av et polypeptid
PE20170142A1 (es) Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma
PE20130199A1 (es) Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
AR088048A1 (es) Señuelos notch1 humanos
NZ724196A (en) Uti fusion proteins
EA202091496A1 (ru) Вариант инсектицидного гена axmi115 и способы его применения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal